Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Arzneimittelforschung. 1995 Mar;45(3A):435-8.

Regulation of proteolytic processing of the amyloid beta-protein precursor by first messengers. A novel potential approach for the treatment of Alzheimer's disease.

Author information

  • 1Department of Neurology, Massachusetts General Hospital, Boston, USA.

Abstract

Amyloid deposits in Alzheimer's disease brains consist of aggregated amyloid beta-peptides (A beta) which are derived by proteolytic processing of the amyloid beta-protein precursor (APP). Proteolytic APP processing can be regulated by the activity of neuronal cell surface receptors including the muscarinic m1 and m3, the serotoninergic 5-HT2 and 5-HT1C, vasopressin and bradykinin receptor subtypes. Receptor stimulation with appropriate agonists rapidly increases the rates of release of the alpha-secretase processing product APPs which is cleaved within the A beta domain and thus is a non-amyloidogenic derivative. Moreover, stimulation of m1 receptors also decreases the formation of A beta, a secreted potentially amyloidogenic and possibly neurotoxic APP fragment. Similar biochemical events occur in stimulation experiments of fresh rat brain slices suggesting that neuronal activity may be involved in regulating APP processing in mammalian brain. Activation of non-amyloidogenic APP processing and inhibition of amyloidogenic processing pathways by subtype-specific agonists of muscarinic, serotoninergic or peptidergic receptors provides a novel approach for the pharmacological modulation of APP processing in Alzheimer's disease.

PMID:
7763340
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk